LYN Gene (LYN Proto-Oncogene, Src Family Tyrosine Kinase)
Comprehensive biomedical resource for LYN gene: function, expression, mutations, and associated diseases.
Gene Information Card
| Symbol | LYN |
|---|---|
| Full Name | LYN proto-oncogene, Src family tyrosine kinase |
| Gene Type | protein-coding |
| Chromosomal Location | 8q12.1 |
| NCBI Gene ID | 4067 ncbi.nlm.nih.gov/gene/4067 |
| Ensembl ID | ENSG00000254087 |
| UniProt ID | P07948 |
| OMIM ID | 165120 |
| HGNC ID | 6735 |
| Aliases | JTK8, p53Lyn, p56Lyn |
Description
LYN encodes a member of the Src family of non-receptor tyrosine kinases. It is widely expressed in hematopoietic cells, neural tissues, and various epithelial cells. LYN functions as a critical regulator of immune receptor signaling, cell proliferation, differentiation, and apoptosis. Aberrant LYN activity is implicated in hematologic malignancies, autoimmune disorders, and solid tumors.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Chronic myeloid leukemia (CML) | LYN overexpression and constitutive activation contribute to BCR-ABL-independent resistance to tyrosine kinase inhibitors. | PMID: 15692054; COSMIC |
| Acute myeloid leukemia (AML) | Activating mutations and increased LYN kinase activity promote leukemogenesis. | PMID: 23327922; ClinVar |
| Systemic lupus erythematosus (SLE) | LYN deficiency or altered signaling disrupts B-cell tolerance and enhances autoantibody production. | PMID: 15356147; OMIM |
| Breast cancer | LYN overexpression correlates with poor prognosis and promotes invasion and metastasis. | PMID: 16980330; COSMIC |
| Colorectal cancer | LYN activation via Src family kinase signaling enhances tumor growth and migration. | PMID: 21502544; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Spleen | 45.2 | High |
| Lymph node | 38.7 | High |
| Bone marrow | 32.1 | High |
| Whole blood | 28.5 | High |
| Brain (cerebellum) | 12.3 | Medium |
| Lung | 8.9 | Low |
| Liver | 4.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K-562 (CML) | 62.4 | High expression; BCR-ABL positive |
| HL-60 (AML) | 55.1 | High expression |
| Raji (Burkitt lymphoma) | 48.7 | High expression |
| MCF7 (breast cancer) | 18.3 | Medium expression |
| HEK293 (embryonic kidney) | 6.5 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1169A>G (p.Tyr390Cys) | Missense | <1% (COSMIC) | Gain-of-function; increased kinase activity |
| c.1280G>A (p.Arg427Gln) | Missense | <1% (COSMIC) | Unknown; located in kinase domain |
| c.1666C>T (p.Arg556*) | Nonsense | <0.1% (ClinVar) | Loss-of-function; truncated protein |
| c.1522G>A (p.Glu508Lys) | Missense | <0.5% (COSMIC) | Gain-of-function; enhanced signaling |
Mutation functional classification
Loss of Function (LOF)
Nonsense mutations (e.g., p.Arg556*) and some missense variants that disrupt kinase activity or protein stability lead to reduced LYN function, associated with autoimmune phenotypes.
Gain of Function (GOF)
Missense mutations in the kinase domain (e.g., p.Tyr390Cys, p.Glu508Lys) increase catalytic activity, promoting oncogenic signaling in hematologic malignancies.
Dominant Negative (DN)
No well-characterized dominant-negative mutations reported for LYN.
View complete mutation data：
Gene Ontology (GO)
| • GO:0004715 | • non-membrane spanning protein tyrosine kinase activity |
| • GO:0005524 | • ATP binding |
| • GO:0005737 | • cytoplasm |
| • GO:0005886 | • plasma membrane |
| • GO:0007169 | • transmembrane receptor protein tyrosine kinase signaling pathway |
| • GO:0038096 | • Fc-gamma receptor signaling pathway involved in phagocytosis |
| • GO:0045087 | • innate immune response |
| • GO:0050852 | • T cell receptor signaling pathway |
Pathways
• B cell receptor signaling pathway (KEGG: hsa04662)
• Fc gamma R-mediated phagocytosis (KEGG: hsa04666)
• Natural killer cell mediated cytotoxicity (KEGG: hsa04650)
• ErbB signaling pathway (KEGG: hsa04012)
• Chemokine signaling pathway (KEGG: hsa04062)
Protein Summary
LYN is a 56 kDa Src family tyrosine kinase composed of SH3, SH2, and tyrosine kinase domains. It is anchored to the plasma membrane via N-terminal myristoylation and palmitoylation. LYN phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) and inhibitory motifs (ITIMs), modulating signaling from B-cell receptors, Fc receptors, and other immune receptors. It also regulates cytoskeletal reorganization and cell adhesion. Dysregulation of LYN contributes to oncogenesis and autoimmunity.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LYN Knockout HEK293 Cell Line | EDJ-KQ574 | Human | 4067 | Details Get a Quote |
| LYN Knockout HeLa Cell Line | EDJ-KQ18031 | Human | 4067 | Details Get a Quote |
| LYN Knockout A-549 Cell Line | EDJ-KQ18970 | Human | 4067 | Details Get a Quote |
| LYN Knockout HCT 116 Cell Line | EDJ-KQ18971 | Human | 4067 | Details Get a Quote |
| LYNX1 Knockout HEK293 Cell Line | EDJ-KQ51646 | Human | 66004 | Details Get a Quote |
| LYNX1 Knockout HeLa Cell Line | EDJ-KQ57117 | Human | 66004 | Details Get a Quote |
| LYNX1 Knockout A-549 Cell Line | EDJ-KQ65631 | Human | 66004 | Details Get a Quote |
| LYNX1 Knockout HCT 116 Cell Line | EDJ-KQ74054 | Human | 66004 | Details Get a Quote |
| LYN Knockout HAP1 Cell Line | EDC07799 | Human | 4067 | Details Get a Quote |
Displaying Records 1 To 9 Of 9 Records
